A father-son garage project spent nearly two decades turning telescope logic into a portable ultrasound system. The first serious proof is in, but the most interesting claims still have to survive larger clinical trials.
VYRSA built a three-product answer to a stubborn source of back pain, won FDA clearance for a stranger kind of implant, and sold to Nevro before its third birthday. The playbook is compact: license hard science, simplify the procedure, and let a bigger sales force carry it.
Exo squeezed three ultrasound probes, real-time AI and the paperwork of a hospital imaging program into one pocket-sized system. The harder trick is making bedside scanning routine rather than exceptional.
The company’s most durable idea is also its smallest: reach the disease through a vessel, an opening or a pinprick - then turn that procedure into a platform.